pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

642 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT782Endpoints585BioPharma Dive224onclive165BioSpace57Fierce Biotech57raps24
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology6Hematology
  • Lonza looks to ride ADC wave with upcoming factory, workforce expansion
    BASEL, Switzerland — Lonza said it wants to own the commercial market for antibody-drug conjugates, with a new manufacturing site set to come online next year and plans to increase its headcount.…
    Endpoints · 2mo ago↗ source
  • Madrigal's Rezdiffra beats estimates; Gilead cuts jobs; Banyan debuts
    🚀 Madrigal Pharmaceuticals' MASH drug beats expectations: The biotech’s Rezdiffra sales came in at $311 million for the first quarter, surpassing analysts’ projections by about $10 million, accord…
    Endpoints · 2mo ago↗ source
  • Former Orbital scientists launch new mRNA therapy startup
    Two scientists think they've solved a technical problem that has kept the mRNA revolution from reaching its full potential. Now, they're launching ParcelBio with $13 million in seed funding to dev…
← prev
page 22 of 26
next →
6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
Endpoints · 2mo ago
↗ source
  • Avalo scores Phase 2 success in comeback bid, raises $375M
    Avalo Therapeutics’ comeback bid surged forward Tuesday afternoon, as the immunology biotech secured a mid-stage trial win in an inflammatory skin disorder. Avalo said that both doses of an exper…
    Endpoints · 2mo ago↗ source
  • GSK goes to China for $1B siRNA deal in Arrowhead's obesity lane
    GSK is further delving into the cardiometabolic space — and deepening its relationship with China biotechs — in a $1 billion biobucks deal with an siRNA startup. The UK pharma is teaming with Suz…
    Endpoints · 2mo ago↗ source
  • CellCentric raises $220M to get multiple myeloma pill to market
    CellCentric has reeled in a massive fund to help it address multiple myeloma patients who have exhausted all other treatment options. The 22-year-old transatlantic biotech has collected a $220 mi…
    Endpoints · 2mo ago↗ source
  • Bayer to buy Perfuse Therapeutics for $300M upfront
    Bayer is committing $300 million upfront to buy ophthalmology biotech Perfuse Therapeutics and its mid-stage program targeting the leading causes of blindness. The deal appears to be Bayer’s firs…
    Endpoints · 2mo ago↗ source
  • Novo Nordisk's Q1 in four words: Pills, pricing, payments and pressure
    A million patients with obesity are already taking Novo Nordisk’s Wegovy pill, CEO Mike Doustdar said Wednesday, despite the market entry of Lilly’s Foundayo. Novo's pill had sales of 2.3 billion…
    Endpoints · 2mo ago↗ source
  • Intercept's next-gen FXR agonist fails Phase 2 in latest setback for Italian-owned pharma
    Intercept Pharmaceuticals' attempt at creating a next-generation FXR agonist for certain forms of liver inflammation appears to have ended. The drug developer's INT-787 showed "no clear evidence…
    Endpoints · 2mo ago↗ source
  • Pfizer's Albert Bourla says he has no mega-merger plans
    The most candid man in pharma strikes again. When asked on Tuesday’s earnings call whether Pfizer would consider a “transformative M&A” deal in the near or medium term, CEO Albert Bourla said…
    Endpoints · 2mo ago↗ source
  • BioNTech to scale down manufacturing, over 1,800 jobs on the line
    BioNTech is making big cuts to its manufacturing footprint. The German company said in its first-quarter earnings release that up to 1,860 manufacturing staff could be impacted by its planned dow…
    Endpoints · 2mo ago↗ source
  • Parsley Health goes in-network nationwide
    When I first heard about Parsley Health close to a decade ago, the startup embodied a few trends I was following closely: primary care startups and cash-pay healthcare. For a ...
    Endpoints · 2mo ago↗ source
  • Second life for gene therapy; Takeda Phase 2/3 win; UK cancer biotech's $83M
    A blood test might predict who will respond to Wegovy; Viridian's thyroid eye disease drug wins another Phase 3; Ideaya drops two GSK-returned assets. 🧬 Second life for a gene therapy: A Clevela…
    Endpoints · 2mo ago↗ source
  • Swiss manufacturing, biotech industry so far unfazed by geopolitics
    BASEL, Switzerland — Pharma manufacturing in Switzerland appears to be unperturbed by the threat of tariffs, but it might take several years before the impact of companies moving production to the…
    Endpoints · 2mo ago↗ source
  • Pfizer ends Trillium-related development as R&D spend jumps
    Pfizer has discontinued the final clinical study stemming from its 2021 acquisition of Trillium Therapeutics, funneling cash primarily toward a host of other cancer and obesity studies. The compa…
    Endpoints · 2mo ago↗ source
  • Microbiome startup raises $48M for immunotherapy and malnutrition treatments
    Scientists trying to understand why cancer immunotherapy works so well for some patients and not others have found a potential answer in one cancer survivor's poop. A biotech startup has studied t…
    Endpoints · 2mo ago↗ source
  • J&J's IBD combo fails Phase 2 studies, but will move into pivotal testing
    Johnson & Johnson will move a treatment for inflammatory bowel disease into Phase 3 studies despite the therapy's failure in two mid-stage trials. The company said that JNJ-4804, a combinatio…
    Endpoints · 2mo ago↗ source
  • Madrigal extends MASH deal streak with Arrowhead drug that J&J didn't want
    Madrigal Pharmaceuticals has made its fourth MASH deal in 10 months, further signaling its ambitions to be not just the first drugmaker for the fatty liver disease, but also the owner of the field'…
    Endpoints · 2mo ago↗ source
  • Healthcare organizations are increasingly building their own AI tools
    Big healthcare organizations are increasingly building their own AI tools, rather than shelling out for tools made by health tech startups that may eventually become free. It’s not uncommon to fi…
    Endpoints · 2mo ago↗ source
  • Cytokinetics succeeds where Bristol Myers failed in heart muscle disease
    Cytokinetics’ pill for a heart muscle disorder called hypertrophic cardiomyopathy could see its addressable market double after it succeeded in a pivotal trial for another form of the disease. Th…
    Endpoints · 2mo ago↗ source
  • Vertex drops mRNA cystic fibrosis program over 'tolerability' issues
    Vertex Pharmaceuticals said it has dropped development of an mRNA-based cystic fibrosis therapy after facing challenges similar to those that have troubled other parts of the field in delivering th…
    Endpoints · 2mo ago↗ source
  • FDA search for new CBER head focused on small group of final candidates
    The FDA has narrowed its search for a new leader of its Center for Biologics Evaluation and Research to three or four final candidates, according to a person familiar with the matter. The agency…
    Endpoints · 2mo ago↗ source
  • Supreme Court restores mifepristone access by mail
    The Supreme Court restored mail ordering of mifepristone, reversing a federal appeals court’s stay. The decision Monday came after makers of the pill asked for an immediate response to a ruling ...
    Endpoints · 2mo ago↗ source
  • Celcuity's breast cancer win; Odyssey plans $205M IPO
    Celcuity’s breast cancer drug wins again: The company said two regimens with its experimental drug gedatolisib succeeded in PIK3CA mutant patients as part of its Phase 3 trial. Last year ...
    Endpoints · 2mo ago↗ source
  • Biotech has a new startup model: Small team, big check and Chinese assets
    A new flavor of company is shaking up how biotechs are built. Instead of launching with eye-popping early-stage science or a new platform, there's a surge of startups with small teams, large chec…
    Endpoints · 2mo ago↗ source